Equities analysts predict that Bio-Techne (NASDAQ:TECH) will post earnings of $1.14 per share for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for Bio-Techne’s earnings. The highest EPS estimate is $1.21 and the lowest is $1.05. Bio-Techne posted earnings per share of $0.97 during the same quarter last year, which suggests a positive year over year growth rate of 17.5%. The business is scheduled to report its next earnings report before the market opens on Wednesday, May 2nd.
On average, analysts expect that Bio-Techne will report full year earnings of $4.32 per share for the current year, with EPS estimates ranging from $4.07 to $4.51. For the next year, analysts expect that the business will report earnings of $4.90 per share, with EPS estimates ranging from $4.52 to $5.15. Zacks’ EPS averages are a mean average based on a survey of research analysts that that provide coverage for Bio-Techne.
Bio-Techne (NASDAQ:TECH) last issued its quarterly earnings data on Tuesday, February 6th. The biotechnology company reported $1.02 EPS for the quarter, beating the Zacks’ consensus estimate of $0.92 by $0.10. The business had revenue of $154.15 million for the quarter, compared to analyst estimates of $145.93 million. Bio-Techne had a return on equity of 14.39% and a net margin of 19.17%. The firm’s revenue for the quarter was up 16.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.81 EPS.
A number of analysts have commented on the company. ValuEngine upgraded Bio-Techne from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. Robert W. Baird raised their price objective on Bio-Techne from $154.00 to $157.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 7th. BidaskClub upgraded Bio-Techne from a “buy” rating to a “strong-buy” rating in a research report on Friday, March 16th. Craig Hallum reiterated a “buy” rating and issued a $160.00 price objective (up previously from $140.00) on shares of Bio-Techne in a research report on Wednesday, February 7th. Finally, Zacks Investment Research downgraded Bio-Techne from a “buy” rating to a “hold” rating in a research report on Saturday, February 3rd. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Bio-Techne presently has a consensus rating of “Buy” and a consensus target price of $148.60.
In other Bio-Techne news, Director Charles A. Dinarello sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $136.06, for a total value of $680,300.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 3.40% of the stock is currently owned by company insiders.
Several institutional investors have recently bought and sold shares of the stock. Xact Kapitalforvaltning AB bought a new position in shares of Bio-Techne during the 4th quarter worth approximately $445,000. APCM Wealth Management for Individuals bought a new position in shares of Bio-Techne during the 4th quarter worth approximately $259,000. MetLife Investment Advisors LLC bought a new position in shares of Bio-Techne during the 4th quarter worth approximately $3,071,000. Vident Investment Advisory LLC lifted its position in shares of Bio-Techne by 78.4% during the 4th quarter. Vident Investment Advisory LLC now owns 7,235 shares of the biotechnology company’s stock worth $937,000 after buying an additional 3,180 shares during the period. Finally, Jane Street Group LLC lifted its position in shares of Bio-Techne by 17.5% during the 4th quarter. Jane Street Group LLC now owns 3,016 shares of the biotechnology company’s stock worth $391,000 after buying an additional 449 shares during the period. Institutional investors and hedge funds own 97.14% of the company’s stock.
TECH traded down $1.07 during midday trading on Thursday, reaching $152.28. The company’s stock had a trading volume of 76,863 shares, compared to its average volume of 177,470. The firm has a market capitalization of $5,733.90, a P/E ratio of 44.53, a price-to-earnings-growth ratio of 2.55 and a beta of 0.70. The company has a quick ratio of 2.49, a current ratio of 3.10 and a debt-to-equity ratio of 0.36. Bio-Techne has a twelve month low of $99.96 and a twelve month high of $154.55.
TRADEMARK VIOLATION NOTICE: “Zacks: Brokerages Anticipate Bio-Techne (TECH) Will Post Earnings of $1.14 Per Share” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/19/zacks-brokerages-anticipate-bio-techne-tech-will-post-earnings-of-1-14-per-share.html.
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates through three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers native and recombinant proteins, monoclonal and polyclonal antibodies, immunoassays, biologically active chemical compounds, and in situ genomic hybridization assays for the research and clinical diagnostics markets.
Get a free copy of the Zacks research report on Bio-Techne (TECH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.